Novartis hemoglobinuria trial meets two primary endpoints
admin Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to…
Read MoreNovartis AG
Novartis to spin off, list Sandoz business
Novartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it as…
Read More